Autoimmune disease Archives

News and Trends 9 Feb 2017

Alma Bio Therapeutics is Aiming to Revolutionize the Treatment of IBD

A new immune modulator to treat Inﬂammatory Bowel Diseases (IBD) is the lead asset in development at Alma Bio Therapeutics. We had the opportunity to meet up with the company’s co-founder and CEO, Binah Baum, to hear more about their fresh approach to treating IBD and other autoimmune diseases. Binah Baum, another female leader in […]

February 9, 2017 - 6 minutesmins - By External Contributor

Screenshot 2017 01 27 at 2.17.05 PM 1 e1485524200727

Startup Scout 27 Jan 2017

Needle-free Treatments for Autoimmune Disorders from Switzerland

It’s back to go back to the mainland. This week’s stop is in Hergiswill, a city by one of the many beautiful seas that can be found in Switzerland. There, the young biotech BioLingus is developing needle-free therapies for chronic diseases. City: Hergiswill, Switzerland Founded: 2014 Employees: 1-10 Financial data: N/A Mission: BioLingus develops non-invasive treatments for autoimmune and inflammatory […]

January 27, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 25 Jan 2017

Update: From Lupus to a Vaccine for Diabetes Type I? Dates Announced

Update (25/01/2016): NeoVacs has announced plans to obtain preclinical proof of concept in 2017 for its type 1 diabetes program and to initiate clinical development in the first half of 2018 with the recommendation of its Scientific Advisory Board. Published on 13/10/2016 Neovacs has announced a research collaboration that could lead to the development of […]

January 25, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Dec 2016

These are our 10 Most Read Biotech Articles of 2016

From the hottest research areas to the most popular city for biotech, which biotech articles have managed to hook our readers the most this year? After an exciting journey of 2 years, Labiotech.eu is now the leading biotech media in Europe, with over 50k monthly readers. To celebrate the end of another amazing year, we wanted […]

December 20, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Dec 2016

Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia?

Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Amryt has taken out a loan from the European Investment Bank to fund […]

December 9, 2016 - 2 minutesmins - By Evelyn Warner

Neovacs lupus erythmatosis kinoid cytokine world day biotech therapy

News and Trends 10 May 2016

Today is World Lupus Day! Meet the people who are fighting this Rare disease

World Lupus Day is an initiative to increase the awareness around this disease which affects more than 5 million people worldwide. Last week in Paris, the biotech company Neovacs, which develops an innovative therapy against lupus, had gathered researchers, entrepreneurs and patients’ associations who are fighting the disease. I was there to meet them and […]

May 10, 2016 - 6 minutesmins - By Joachim Eeckhout

News and Trends 6 May 2016

Interview with Two Key People of the Fight Against Lupus

I was in Paris this week in the building of the Rare Disease Alliance, an association helping patients affected by a rare disease. The association lend their space to Neovacs, a biotech company from Paris, which was organising a gathering of experts of lupus. Lupus is one of the most common rare disease and affects more than 5 million […]

May 6, 2016 - 1 minutemin - By Joachim Eeckhout

txcell ospedale san raffaele lupus nephritis car treg

News and Trends 27 Apr 2016

CAR-T for Lupus with French-Italian Partnership

TxCell and Ospedale San Raffaele have partnered up to research a new treatment for Lupus, based on engineered regulatory T-cells (CAR-Treg). TxCell is developing immunotherapies based on the discovery of a type of T-cells that have anti-inflammatory properties – regulatory T lymphocytes (Tregs). Tregs have already yielded two candidates. Osave is currently on phase IIb […]

April 27, 2016 - 2 minutesmins - By Denise Neves Gameiro

geneuro euronext multiple sclerosis biotech

News and Trends 16 Apr 2016

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

We last wrote about GeNeuro in January, when they announced the launch of an IPO for their Multiple Sclerosis phase IIb trial. Now, as of yesterday they are listed on the Euronext Paris market. GeNeuro (in Geneva) is developing therapies and diagnostic tools for diseases associated with the expression of the human endogenous retrovirus MSRV, such […]

April 16, 2016 - 2 minutesmins - By Dani Bancroft

boehringer ingelheim abbvie psoriasis interleukin23 bi655066 bi655066 Crohns asthma psoriatic arthritis

News and Trends 9 Mar 2016

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Boehringer Ingelheim (Germany) has entered a new collaboration with AbbVie (US) to develop two new candidates for immune diseases, including psoriasis and Crohn’s disease. Therapies for immune diseases continue to attract Pharma’s attention (and money). This time, two of 25 leading Big Pharma worldwide, AbbVie and Boehringer Ingelheim, have partnered to develop 2 different immunological candidates. […]

March 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

osteoporosis vertebral column denosumab amgen ucb

News and Trends 22 Feb 2016

Can this Positive Phase III Immunotherapy End Spinal Fractures due to Osteoporosis?

UCB (Belgium) has a monoclonal antibody candidate (romozumab) which has met its primary endpoints for a phase III Osteoporosis trial, FRAME in partnership with Amgen. The drug showed 75% improvement (compared to placebo) and few side effects. UCB in Brussels is developing immunotherapies for a range of chronic diseases, which has now gotten good phase III results for an […]

February 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

alpaca nejm purpura thrombocytopenia blood titan hercules

News and Trends 16 Feb 2016

World’s Best Journal in Medicine Publishes on Phase II Llama Antibodies

Ablynx, the llama antibody biotech in Belgium, has now proven to be on solid ground regarding their orphan drug for a rare blood disease. Now the New England Journal of Medicine has published their phase II results. Ablynx often makes our biotech headlines, be it with the curious science of their nanobody platform or with their partnerships with […]

February 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Autoimmune disease

Alma Bio Therapeutics is Aiming to Revolutionize the Treatment of IBD

Needle-free Treatments for Autoimmune Disorders from Switzerland

Update: From Lupus to a Vaccine for Diabetes Type I? Dates Announced

These are our 10 Most Read Biotech Articles of 2016

Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia?

Today is World Lupus Day! Meet the people who are fighting this Rare disease

Interview with Two Key People of the Fight Against Lupus

CAR-T for Lupus with French-Italian Partnership

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Can this Positive Phase III Immunotherapy End Spinal Fractures due to Osteoporosis?

World’s Best Journal in Medicine Publishes on Phase II Llama Antibodies

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!